Goldman Sachs
HRTX icon

Goldman Sachs’s Heron Therapeutics HRTX Stock Holding History

Goldman Sachs’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$846K Buy
1,056,944
+67,148
+7% +$77.8K ﹤0.01% 5219
2025
Q4 		$1.29M Sell
989,796
-335,006
-25% -$414K ﹤0.01% 4934
2025
Q3 		$1.67M Buy
1,324,802
+281,492
+27% +$446K ﹤0.01% 4630
2025
Q2 		$2.16M Buy
1,043,310
+14,632
+1% +$29.9K ﹤0.01% 4122
2025
Q1 		$2.26M Buy
1,028,678
+373,518
+57% +$725K ﹤0.01% 4050
2024
Q4 		$1M Sell
655,160
-1,051,992
-62% -$1.71M ﹤0.01% 4818
2024
Q3 		$3.4M Buy
1,707,152
+292,083
+21% +$697K ﹤0.01% 3693
2024
Q2 		$4.95M Buy
1,415,069
+14,665
+1% +$45.1K ﹤0.01% 3162
2024
Q1 		$3.88M Buy
1,400,404
+415,753
+42% +$1.05M ﹤0.01% 3334
2023
Q4 		$1.67M Buy
984,651
+378,845
+63% +$417K ﹤0.01% 4052
2023
Q3 		$624K Buy
605,806
+39,742
+7% +$56.6K ﹤0.01% 4542
2023
Q2 		$657K Buy
566,064
+161,755
+40% +$288K ﹤0.01% 4590
2023
Q1 		$611K Sell
404,309
-748,642
-65% -$1.87M ﹤0.01% 4722
2022
Q4 		$2.88M Sell
1,152,951
-1,146,102
-50% -$3.69M ﹤0.01% 3645
2022
Q3 		$9.7M Buy
2,299,053
+1,024,354
+80% +$4.01M ﹤0.01% 2534
2022
Q2 		$3.56M Sell
1,274,699
-1,004,899
-44% -$4.04M ﹤0.01% 3511
2022
Q1 		$13M Buy
2,279,598
+361,188
+19% +$2.64M ﹤0.01% 2427
2021
Q4 		$17.5M Buy
1,918,410
+316,554
+20% +$3.23M ﹤0.01% 2238
2021
Q3 		$17.1M Buy
1,601,856
+908,890
+131% +$11.1M ﹤0.01% 2223
2021
Q2 		$10.8M Sell
692,966
-532,319
-43% -$8.47M ﹤0.01% 2625
2021
Q1 		$19.9M Buy
1,225,285
+77,343
+7% +$1.38M 0.01% 1935
2020
Q4 		$24.3M Buy
1,147,942
+114,958
+11% +$2M 0.01% 1703
2020
Q3 		$15.3M Sell
1,032,984
-153,971
-13% -$2.4M ﹤0.01% 1960
2020
Q2 		$17.5M Sell
1,186,955
-298,572
-20% -$4.91M 0.01% 1795
2020
Q1 		$17.4M Sell
1,485,527
-52,092
-3% -$979K 0.01% 1619
2019
Q4 		$36.1M Buy
1,537,619
+847,578
+123% +$18.8M 0.01% 1390
2019
Q3 		$12.8M Sell
690,041
-62,370
-8% -$1.15M ﹤0.01% 2149
2019
Q2 		$14M Sell
752,411
-38,660
-5% -$772K ﹤0.01% 2125
2019
Q1 		$19.3M Buy
791,071
+94,665
+14% +$2.48M 0.01% 1901
2018
Q4 		$18.1M Buy
696,406
+153,086
+28% +$4.21M 0.01% 1884
2018
Q3 		$17.2M Buy
543,320
+63,293
+13% +$2.36M ﹤0.01% 2029
2018
Q2 		$18.6M Buy
480,027
+167,595
+54% +$5.34M 0.01% 1927
2018
Q1 		$8.62M Buy
312,432
+166,560
+114% +$3.78M ﹤0.01% 2467
2017
Q4 		$2.64M Sell
145,872
-130,031
-47% -$2.12M ﹤0.01% 3559
2017
Q3 		$4.46M Sell
275,903
-142,377
-34% -$2.23M ﹤0.01% 3266
2017
Q2 		$5.79M Buy
418,280
+198,562
+90% +$2.88M ﹤0.01% 2939
2017
Q1 		$3.3M Buy
219,718
+192,604
+710% +$2.67M ﹤0.01% 3299
2016
Q4 		$355K Sell
27,114
-10,703
-28% -$168K ﹤0.01% 5346
2016
Q3 		$652K Buy
37,817
+29,404
+350% +$546K ﹤0.01% 4791
2016
Q2 		$152K Sell
8,413
-146,258
-95% -$2.86M ﹤0.01% 5883
2016
Q1 		$2.94M Buy
154,671
+107,754
+230% +$2.13M ﹤0.01% 3156
2015
Q4 		$1.25M Sell
46,917
-689,922
-94% -$18.4M ﹤0.01% 4070
2015
Q3 		$18M Buy
736,839
+721,568
+4,725% +$24M 0.01% 1787
2015
Q2 		$476K Buy
+15,271
New +$287K ﹤0.01% 5259
2014
Q3 		– Sell
-39,986
Closed -$493K – 7169
2014
Q2 		$493K Buy
39,986
+23,183
+138% +$277K ﹤0.01% 5332
2014
Q1 		$234K Buy
+16,803
New +$224K ﹤0.01% 5947

Other funds holding HRTX

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
CC
Clearline Capital New York $1.93B AUM 38.13% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
PCM
Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return

Goldman Sachs's HRTX Position: Q1 2026 in Review

Goldman Sachs increased its Heron Therapeutics (HRTX) stake by 6.8% in Q1 2026, buying an estimated $77.8K and bringing the position to 1,056,944 shares worth $846K. The position accounts for ﹤0.01% of the portfolio, ranked #5219.

Goldman Sachs first reported a position in HRTX in Q1 2014 and has held it in 46 quarters since. The position peaked at $36.1M in Q4 2019. 167 funds tracked by Wall St. Rank hold HRTX as of Q1 2026.

  • Goldman Sachs held 1,056,944 shares of Heron Therapeutics worth $846K as of Q1 2026.
  • Goldman Sachs bought 67,148 Heron Therapeutics shares in Q1 2026, an estimated $77.8K.
  • Heron Therapeutics made up ﹤0.01% of Goldman Sachs's portfolio in Q1 2026, its #5219 holding.
  • Goldman Sachs first reported a position in Heron Therapeutics in Q1 2014 and has held it in 46 quarters since.
  • Goldman Sachs's Heron Therapeutics position peaked at $36.1M in Q4 2019.
  • 167 funds tracked by Wall St. Rank held Heron Therapeutics as of Q1 2026.

Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.